Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00681395 · ClinicalTrials.gov registry record · Phase 1
Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Relative to That From the Co-administration of ABT-335 and Rosuvastatin Calcium
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT00681395 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 64 participants.
The verdict
NCT00681395, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
To evaluate safety and compare the pharmacokinetic parameters from the fixed dose combination ABT-143 relative to that from the co-administration of the two monotherapies.
Interventions
- DRUG Rosuvastatin
- DRUG ABT-335
- DRUG ABT-143
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2008-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00681395
The ClinicalTrials.gov registry entry for NCT00681395 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Rosuvastatin is the first listed.
NCT00681395 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00681395 about?
NCT00681395 is a clinical study titled "Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Relative to That From the Co-administration of ABT-335 and Rosuvastatin Calcium". To evaluate safety and compare the pharmacokinetic parameters from the fixed dose combination ABT-143 relative to that from the co-administration of the two monotherapies.
What is the current status of trial NCT00681395?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2008-05.
What interventions are being tested in trial NCT00681395?
The interventions under investigation include: Rosuvastatin (DRUG), ABT-335 (DRUG), ABT-143 (DRUG).
Who is sponsoring clinical trial NCT00681395?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.